精准医疗视角下中国良性前列腺增生手术治疗的挑战与技术转型

Challenges and technological transformation of surgical treatment for benign prostatic hyperplasia in China from the perspective of precision medicine

ES评分 0

DOI 10.12208/j.imrf.20250009
刊名
International Medical Research Frontier
年,卷(期) 2025, 9(1)
作者
作者单位

浙江桐轩医疗科技有限公司 浙江台州

摘要
良性前列腺增生(Benign Prostatic Hyperplasia, BPH)是中国老龄男性中常见的泌尿系统疾病,显著影响生活质量。尽管传统治疗方式如药物治疗和经尿道前列腺切除术(TURP)在一定程度上缓解了症状,但存在疗效有限、并发症多、恢复周期长等问题,尤其在高龄或合并基础疾病患者中更为突出。近年来,微创治疗手段逐渐兴起,但大多数仍以组织切除为核心,难以满足器官功能保留和术后快速恢复的双重需求。本文系统分析了BPH微创治疗在中国临床实践中的困境与限制,进一步聚焦于新兴技术——超微创前列腺扩开术(Prostatic Urethral Dilation, PUD)及其核心器械“长寿棒”前列腺扩裂导管的发展路径、技术原理和临床优势。在精准医疗理念指导下,PUD技术的多学科协作路径及个体化治疗调整策略,也为BPH治疗提供了新的临床范式。未来,随着材料技术、影像导航及临床大数据的发展,PUD有望成为BPH微创精准治疗的主流选择。
Abstract
Benign prostatic hyperplasia (BPH) is common among aging men in China, often leading to lower urinary tract symptoms (LUTS). Traditional treatments such as TURP are effective but associated with complications and limited suitability for elderly or high-risk patients. Precision medicine calls for safer, individualized, and function-preserving approaches. This study reviews the clinical application of prostatic urethral dilation (PUD) using the Longevity bar—a non-resective, dual-balloon device made of TPU material with excellent biocompatibility and mechanical strength. It aligns with precision medicine goals and is especially suitable for patients seeking organ preservation and rapid recovery. In the future, with advances in material science, imaging navigation, and clinical data, PUD is expected to become a mainstream option for minimally invasive and precision treatment of BPH.
关键词
良性前列腺增生;超微创前列腺扩开术;长寿棒;微创治疗;精准医疗
KeyWord
Benign prostatic hyperplasia; Prostatic urethral dilation; Longevity bar; Minimally invasive therapy; Precision medicine
基金项目
页码 37-40
  • 参考文献
  • 相关文献
  • 引用本文

沈坤,张大伟,陈纯,虞蕾楠*. 精准医疗视角下中国良性前列腺增生手术治疗的挑战与技术转型 [J]. 国际医药研究前沿. 2025; 9; (1). 37 - 40.

  • 文献评论

相关学者

相关机构